Risk assessment and prognostic aspect of coagulopathy in COVID-19

Adv Respir Med. 2021;89(1):90-91. doi: 10.5603/ARM.a2020.0191. Epub 2021 Feb 9.

Abstract

Since December 2019, the rapid spread of SARS CoV-2 across the border, shuffled into a world pandemic situation with an alarming rate of morbidity and mortality. Concerns are mounting as the reports indicate tangled circumstances among the COVID-19 patients due to blood coagulopathy followed by organ dysfunction. COVID-19 induced an alteration in coagulation function increase the risk of pulmonary embolism and deep vein thrombosis associated with poor prognosis as well as high mortality. An elevated level D-dimer and other fibrin degrading protein are documented among the patients with COVID-19; especially in severe cases. Differences in coagulopathy among severe and non-severe cases, required prompt attention to adopt a more effective management strategy.

Keywords: COVID-19; D-dimer; blood coagulopathy; embolism; thrombosis.

Publication types

  • Letter

MeSH terms

  • Blood Coagulation Disorders / epidemiology
  • Blood Coagulation Disorders / metabolism*
  • COVID-19 / complications*
  • COVID-19 / epidemiology
  • COVID-19 / metabolism
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • Humans
  • Incidence
  • Prognosis
  • Thrombosis / metabolism

Substances

  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D